{
  "directed": true,
  "graph": {
    "annotation_list": {},
    "annotation_pattern": {
      "Species": "^\\d+$"
    },
    "annotation_url": {
      "Anatomy": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/anatomy/anatomy-20170511.belanno",
      "Confidence": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/confidence/confidence-1.0.0.belanno",
      "MeSHAnatomy": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/mesh-anatomy/mesh-anatomy-20170511.belanno",
      "MeSHDisease": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/mesh-diseases/mesh-diseases-20170511.belanno"
    },
    "document_metadata": {
      "authors": "Yojana Gadiya",
      "contact": "charles.hoyt@scai.fraunhofer.de",
      "copyright": "Copyright Â© 2019 Fraunhofer Institute SCAI, All rights reserved.",
      "description": "",
      "licenses": "CC BY 4.0",
      "name": "First-in-man tau vaccine targeting structural determinants essential for pathological tau-tau interaction reduces tau oligomerisation and neurofibrillary degeneration in an Alzheimer's disease model",
      "version": "1.0.0"
    },
    "namespace_pattern": {},
    "namespace_url": {
      "CONSO": "https://raw.githubusercontent.com/pharmacome/conso/757cbc1e7215da9fdd67bc73b14fbce59736cbdb/export/conso-names.belns",
      "DOID": "https://raw.githubusercontent.com/pharmacome/conso/c0c576e3d3ab9b25a3982251a4ee2fd7c49e1679/external/doid-names.belns",
      "GO": "https://raw.githubusercontent.com/pharmacome/conso/d9d270e11aac480542c412d4222983a5f042b8ae/external/go-names.belns",
      "HGNC": "https://raw.githubusercontent.com/pharmacome/conso/c328ad964c08967a0417a887510b97b965a62fa5/external/hgnc-names.belns",
      "HP": "https://raw.githubusercontent.com/pharmacome/conso/d9d270e11aac480542c412d4222983a5f042b8ae/external/hp-names.belns",
      "MESH": "https://raw.githubusercontent.com/pharmacome/conso/f02c6ad4a4791a8ed45448513b9de8c8f1b00c87/external/mesh-names.belns"
    },
    "path": "immunotherapy/kontsekova2014_2.bel",
    "pybel_version": "0.14.10"
  },
  "links": [
    {
      "key": "14e51b490dbdb3cd2cbb7026ec85374e",
      "relation": "partOf",
      "source": 3,
      "target": 15
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHDisease": {
          "Alzheimer Disease": true
        },
        "Species": {
          "10116": true
        }
      },
      "citation": {
        "authors": [
          "Kontsekova E",
          "Kovacech B",
          "Novak M",
          "Novak P",
          "Zilka N"
        ],
        "date": "2014-01-01",
        "db": "PubMed",
        "db_id": "25478017",
        "db_name": "First-in-man tau vaccine targeting structural determinants essential for pathological tau-tau interaction reduces tau oligomerisation and neurofibrillary degeneration in an Alzheimer's disease model.",
        "first": "Kontsekova E",
        "journal": "Alzheimer's research & therapy",
        "last": "Novak M",
        "pages": "44",
        "volume": "6"
      },
      "evidence": "Importantly, the analysed antibodies showed statistically significantly higher binding activity to the tau peptide and to mis-disordered tau 150-391/4R, than to physiological tau 2N4R (P = 0.0003 and P = 0.0028, respectively) (Figure 1B).",
      "key": "d21bd27cf83610b8dbb548e264d38eca",
      "line": 89,
      "relation": "directlyIncreases",
      "source": 3,
      "target": 15
    },
    {
      "key": "77670ba85e7b5891b2c775e8583cf2f5",
      "relation": "partOf",
      "source": 3,
      "target": 13
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHDisease": {
          "Alzheimer Disease": true
        },
        "Species": {
          "10116": true
        }
      },
      "citation": {
        "authors": [
          "Kontsekova E",
          "Kovacech B",
          "Novak M",
          "Novak P",
          "Zilka N"
        ],
        "date": "2014-01-01",
        "db": "PubMed",
        "db_id": "25478017",
        "db_name": "First-in-man tau vaccine targeting structural determinants essential for pathological tau-tau interaction reduces tau oligomerisation and neurofibrillary degeneration in an Alzheimer's disease model.",
        "first": "Kontsekova E",
        "journal": "Alzheimer's research & therapy",
        "last": "Novak M",
        "pages": "44",
        "volume": "6"
      },
      "evidence": "Importantly, the analysed antibodies showed statistically significantly higher binding activity to the tau peptide and to mis-disordered tau 150-391/4R, than to physiological tau 2N4R (P = 0.0003 and P = 0.0028, respectively) (Figure 1B).",
      "key": "61f832d654a43e2247f5438ebdfc5599",
      "line": 90,
      "relation": "directlyIncreases",
      "source": 3,
      "target": 13
    },
    {
      "key": "c362239e4844f0693ef724b389cde0f6",
      "relation": "partOf",
      "source": 3,
      "target": 14
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHDisease": {
          "Alzheimer Disease": true
        },
        "Species": {
          "10116": true
        }
      },
      "citation": {
        "authors": [
          "Kontsekova E",
          "Kovacech B",
          "Novak M",
          "Novak P",
          "Zilka N"
        ],
        "date": "2014-01-01",
        "db": "PubMed",
        "db_id": "25478017",
        "db_name": "First-in-man tau vaccine targeting structural determinants essential for pathological tau-tau interaction reduces tau oligomerisation and neurofibrillary degeneration in an Alzheimer's disease model.",
        "first": "Kontsekova E",
        "journal": "Alzheimer's research & therapy",
        "last": "Novak M",
        "pages": "44",
        "volume": "6"
      },
      "evidence": "Importantly, the analysed antibodies showed statistically significantly higher binding activity to the tau peptide and to mis-disordered tau 150-391/4R, than to physiological tau 2N4R (P = 0.0003 and P = 0.0028, respectively) (Figure 1B).",
      "key": "dc4d8335d05880d372a27f9f26cc5efe",
      "line": 91,
      "relation": "directlyIncreases",
      "source": 3,
      "target": 14
    },
    {
      "key": "76b7729d39268e0b4ef998d4c06c1698",
      "relation": "partOf",
      "source": 3,
      "target": 12
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHDisease": {
          "Alzheimer Disease": true
        },
        "Species": {
          "10116": true
        }
      },
      "citation": {
        "authors": [
          "Kontsekova E",
          "Kovacech B",
          "Novak M",
          "Novak P",
          "Zilka N"
        ],
        "date": "2014-01-01",
        "db": "PubMed",
        "db_id": "25478017",
        "db_name": "First-in-man tau vaccine targeting structural determinants essential for pathological tau-tau interaction reduces tau oligomerisation and neurofibrillary degeneration in an Alzheimer's disease model.",
        "first": "Kontsekova E",
        "journal": "Alzheimer's research & therapy",
        "last": "Novak M",
        "pages": "44",
        "volume": "6"
      },
      "evidence": "Immunisation with tau vaccine induced significant reduction of the level of highly phosphorylated forms of truncated tau (30 to 36 kDa), tau oligomers (above 36 kDa) and full-length tau (above 43 kDa) revealed by measurement with pan-tau monoclonal antibody DC25 (P = 0.0322) (Figure 2A and F).",
      "key": "c3af47a17a8e1580caeccdb659a7e8a9",
      "line": 122,
      "relation": "directlyDecreases",
      "source": 3,
      "target": 28
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHDisease": {
          "Alzheimer Disease": true
        },
        "Species": {
          "10116": true
        }
      },
      "citation": {
        "authors": [
          "Kontsekova E",
          "Kovacech B",
          "Novak M",
          "Novak P",
          "Zilka N"
        ],
        "date": "2014-01-01",
        "db": "PubMed",
        "db_id": "25478017",
        "db_name": "First-in-man tau vaccine targeting structural determinants essential for pathological tau-tau interaction reduces tau oligomerisation and neurofibrillary degeneration in an Alzheimer's disease model.",
        "first": "Kontsekova E",
        "journal": "Alzheimer's research & therapy",
        "last": "Novak M",
        "pages": "44",
        "volume": "6"
      },
      "evidence": "Immunisation with tau vaccine induced significant reduction of the level of highly phosphorylated forms of truncated tau (30 to 36 kDa), tau oligomers (above 36 kDa) and full-length tau (above 43 kDa) revealed by measurement with pan-tau monoclonal antibody DC25 (P = 0.0322) (Figure 2A and F).",
      "key": "bb311eb46cf6c4f357133b5c364d3332",
      "line": 123,
      "relation": "directlyDecreases",
      "source": 3,
      "target": 26
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHDisease": {
          "Alzheimer Disease": true
        },
        "Species": {
          "10116": true
        }
      },
      "citation": {
        "authors": [
          "Kontsekova E",
          "Kovacech B",
          "Novak M",
          "Novak P",
          "Zilka N"
        ],
        "date": "2014-01-01",
        "db": "PubMed",
        "db_id": "25478017",
        "db_name": "First-in-man tau vaccine targeting structural determinants essential for pathological tau-tau interaction reduces tau oligomerisation and neurofibrillary degeneration in an Alzheimer's disease model.",
        "first": "Kontsekova E",
        "journal": "Alzheimer's research & therapy",
        "last": "Novak M",
        "pages": "44",
        "volume": "6"
      },
      "evidence": "These results show that the immunisation significantly reduced early forms of pathological tau (represented by monomers, dimers and oligomers) and late forms of pathological tau polymers (represented by paired helical filaments (PHFs)) as well.",
      "key": "9f60f498611504d0f923dee8f83ce2ec",
      "line": 152,
      "relation": "decreases",
      "source": 3,
      "target": 26
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHDisease": {
          "Alzheimer Disease": true
        },
        "Species": {
          "10116": true
        }
      },
      "citation": {
        "authors": [
          "Kontsekova E",
          "Kovacech B",
          "Novak M",
          "Novak P",
          "Zilka N"
        ],
        "date": "2014-01-01",
        "db": "PubMed",
        "db_id": "25478017",
        "db_name": "First-in-man tau vaccine targeting structural determinants essential for pathological tau-tau interaction reduces tau oligomerisation and neurofibrillary degeneration in an Alzheimer's disease model.",
        "first": "Kontsekova E",
        "journal": "Alzheimer's research & therapy",
        "last": "Novak M",
        "pages": "44",
        "volume": "6"
      },
      "evidence": "Immunisation with tau vaccine induced significant reduction of the level of highly phosphorylated forms of truncated tau (30 to 36 kDa), tau oligomers (above 36 kDa) and full-length tau (above 43 kDa) revealed by measurement with pan-tau monoclonal antibody DC25 (P = 0.0322) (Figure 2A and F).",
      "key": "cc3cbfd6d17bb461901bd75e103b38dd",
      "line": 124,
      "relation": "directlyDecreases",
      "source": 3,
      "target": 27
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHDisease": {
          "Alzheimer Disease": true
        },
        "Species": {
          "10116": true
        }
      },
      "citation": {
        "authors": [
          "Kontsekova E",
          "Kovacech B",
          "Novak M",
          "Novak P",
          "Zilka N"
        ],
        "date": "2014-01-01",
        "db": "PubMed",
        "db_id": "25478017",
        "db_name": "First-in-man tau vaccine targeting structural determinants essential for pathological tau-tau interaction reduces tau oligomerisation and neurofibrillary degeneration in an Alzheimer's disease model.",
        "first": "Kontsekova E",
        "journal": "Alzheimer's research & therapy",
        "last": "Novak M",
        "pages": "44",
        "volume": "6"
      },
      "evidence": "Moreover, analysis with phospho-dependent monoclonal antibodies revealed significant reduction of the levels of insoluble tau species phosphorylated at Thr217 (pThr217, P = 0.0094; Figure 2B and F), pThr231 (DC209, P = 0.0077; Figure 2C and F), pSer202/pThr205 (AT8, P = 0.0112; Figure 2D and F) and pThr181 (DC179, P = 0.0100; Figure 2E and F).",
      "key": "82754945f4d7b14d1d5658bb05093fed",
      "line": 136,
      "relation": "directlyDecreases",
      "source": 3,
      "target": 34
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHDisease": {
          "Alzheimer Disease": true
        },
        "Species": {
          "10116": true
        }
      },
      "citation": {
        "authors": [
          "Kontsekova E",
          "Kovacech B",
          "Novak M",
          "Novak P",
          "Zilka N"
        ],
        "date": "2014-01-01",
        "db": "PubMed",
        "db_id": "25478017",
        "db_name": "First-in-man tau vaccine targeting structural determinants essential for pathological tau-tau interaction reduces tau oligomerisation and neurofibrillary degeneration in an Alzheimer's disease model.",
        "first": "Kontsekova E",
        "journal": "Alzheimer's research & therapy",
        "last": "Novak M",
        "pages": "44",
        "volume": "6"
      },
      "evidence": "Moreover, analysis with phospho-dependent monoclonal antibodies revealed significant reduction of the levels of insoluble tau species phosphorylated at Thr217 (pThr217, P = 0.0094; Figure 2B and F), pThr231 (DC209, P = 0.0077; Figure 2C and F), pSer202/pThr205 (AT8, P = 0.0112; Figure 2D and F) and pThr181 (DC179, P = 0.0100; Figure 2E and F).",
      "key": "840f5b1c175fff905a46c49d9a9c8c91",
      "line": 137,
      "relation": "directlyDecreases",
      "source": 3,
      "target": 35
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHDisease": {
          "Alzheimer Disease": true
        },
        "Species": {
          "10116": true
        }
      },
      "citation": {
        "authors": [
          "Kontsekova E",
          "Kovacech B",
          "Novak M",
          "Novak P",
          "Zilka N"
        ],
        "date": "2014-01-01",
        "db": "PubMed",
        "db_id": "25478017",
        "db_name": "First-in-man tau vaccine targeting structural determinants essential for pathological tau-tau interaction reduces tau oligomerisation and neurofibrillary degeneration in an Alzheimer's disease model.",
        "first": "Kontsekova E",
        "journal": "Alzheimer's research & therapy",
        "last": "Novak M",
        "pages": "44",
        "volume": "6"
      },
      "evidence": "Moreover, analysis with phospho-dependent monoclonal antibodies revealed significant reduction of the levels of insoluble tau species phosphorylated at Thr217 (pThr217, P = 0.0094; Figure 2B and F), pThr231 (DC209, P = 0.0077; Figure 2C and F), pSer202/pThr205 (AT8, P = 0.0112; Figure 2D and F) and pThr181 (DC179, P = 0.0100; Figure 2E and F).",
      "key": "501a8d6eed819f63449faaf1274d9789",
      "line": 138,
      "relation": "directlyDecreases",
      "source": 3,
      "target": 29
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHDisease": {
          "Alzheimer Disease": true
        },
        "Species": {
          "10116": true
        }
      },
      "citation": {
        "authors": [
          "Kontsekova E",
          "Kovacech B",
          "Novak M",
          "Novak P",
          "Zilka N"
        ],
        "date": "2014-01-01",
        "db": "PubMed",
        "db_id": "25478017",
        "db_name": "First-in-man tau vaccine targeting structural determinants essential for pathological tau-tau interaction reduces tau oligomerisation and neurofibrillary degeneration in an Alzheimer's disease model.",
        "first": "Kontsekova E",
        "journal": "Alzheimer's research & therapy",
        "last": "Novak M",
        "pages": "44",
        "volume": "6"
      },
      "evidence": "Moreover, analysis with phospho-dependent monoclonal antibodies revealed significant reduction of the levels of insoluble tau species phosphorylated at Thr217 (pThr217, P = 0.0094; Figure 2B and F), pThr231 (DC209, P = 0.0077; Figure 2C and F), pSer202/pThr205 (AT8, P = 0.0112; Figure 2D and F) and pThr181 (DC179, P = 0.0100; Figure 2E and F).",
      "key": "7678e55d2721a3b232d6e033ef03af7e",
      "line": 139,
      "relation": "directlyDecreases",
      "source": 3,
      "target": 32
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHDisease": {
          "Alzheimer Disease": true
        },
        "Species": {
          "10116": true
        }
      },
      "citation": {
        "authors": [
          "Kontsekova E",
          "Kovacech B",
          "Novak M",
          "Novak P",
          "Zilka N"
        ],
        "date": "2014-01-01",
        "db": "PubMed",
        "db_id": "25478017",
        "db_name": "First-in-man tau vaccine targeting structural determinants essential for pathological tau-tau interaction reduces tau oligomerisation and neurofibrillary degeneration in an Alzheimer's disease model.",
        "first": "Kontsekova E",
        "journal": "Alzheimer's research & therapy",
        "last": "Novak M",
        "pages": "44",
        "volume": "6"
      },
      "evidence": "Moreover, analysis with phospho-dependent monoclonal antibodies revealed significant reduction of the levels of insoluble tau species phosphorylated at Thr217 (pThr217, P = 0.0094; Figure 2B and F), pThr231 (DC209, P = 0.0077; Figure 2C and F), pSer202/pThr205 (AT8, P = 0.0112; Figure 2D and F) and pThr181 (DC179, P = 0.0100; Figure 2E and F).",
      "key": "c835773835a714e5a0a96f9f8ea9e72a",
      "line": 140,
      "relation": "directlyDecreases",
      "source": 3,
      "target": 31
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHDisease": {
          "Alzheimer Disease": true
        },
        "Species": {
          "10116": true
        }
      },
      "citation": {
        "authors": [
          "Kontsekova E",
          "Kovacech B",
          "Novak M",
          "Novak P",
          "Zilka N"
        ],
        "date": "2014-01-01",
        "db": "PubMed",
        "db_id": "25478017",
        "db_name": "First-in-man tau vaccine targeting structural determinants essential for pathological tau-tau interaction reduces tau oligomerisation and neurofibrillary degeneration in an Alzheimer's disease model.",
        "first": "Kontsekova E",
        "journal": "Alzheimer's research & therapy",
        "last": "Novak M",
        "pages": "44",
        "volume": "6"
      },
      "evidence": "These results show that the immunisation significantly reduced early forms of pathological tau (represented by monomers, dimers and oligomers) and late forms of pathological tau polymers (represented by paired helical filaments (PHFs)) as well.",
      "key": "44c064b5c0b7064df26b88358367e4fe",
      "line": 149,
      "relation": "decreases",
      "source": 3,
      "target": 43
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHDisease": {
          "Alzheimer Disease": true
        },
        "Species": {
          "10116": true
        }
      },
      "citation": {
        "authors": [
          "Kontsekova E",
          "Kovacech B",
          "Novak M",
          "Novak P",
          "Zilka N"
        ],
        "date": "2014-01-01",
        "db": "PubMed",
        "db_id": "25478017",
        "db_name": "First-in-man tau vaccine targeting structural determinants essential for pathological tau-tau interaction reduces tau oligomerisation and neurofibrillary degeneration in an Alzheimer's disease model.",
        "first": "Kontsekova E",
        "journal": "Alzheimer's research & therapy",
        "last": "Novak M",
        "pages": "44",
        "volume": "6"
      },
      "evidence": "These results show that the immunisation significantly reduced early forms of pathological tau (represented by monomers, dimers and oligomers) and late forms of pathological tau polymers (represented by paired helical filaments (PHFs)) as well.",
      "key": "ec53bdd541631fd282714ac3020e85d4",
      "line": 150,
      "relation": "decreases",
      "source": 3,
      "target": 19
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHDisease": {
          "Alzheimer Disease": true
        },
        "Species": {
          "10116": true
        }
      },
      "citation": {
        "authors": [
          "Kontsekova E",
          "Kovacech B",
          "Novak M",
          "Novak P",
          "Zilka N"
        ],
        "date": "2014-01-01",
        "db": "PubMed",
        "db_id": "25478017",
        "db_name": "First-in-man tau vaccine targeting structural determinants essential for pathological tau-tau interaction reduces tau oligomerisation and neurofibrillary degeneration in an Alzheimer's disease model.",
        "first": "Kontsekova E",
        "journal": "Alzheimer's research & therapy",
        "last": "Novak M",
        "pages": "44",
        "volume": "6"
      },
      "evidence": "These results show that the immunisation significantly reduced early forms of pathological tau (represented by monomers, dimers and oligomers) and late forms of pathological tau polymers (represented by paired helical filaments (PHFs)) as well.",
      "key": "f59e1b04e9df4b318fe55dee8950c090",
      "line": 151,
      "relation": "decreases",
      "source": 3,
      "target": 20
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHDisease": {
          "Alzheimer Disease": true
        },
        "Species": {
          "10116": true
        }
      },
      "citation": {
        "authors": [
          "Kontsekova E",
          "Kovacech B",
          "Novak M",
          "Novak P",
          "Zilka N"
        ],
        "date": "2014-01-01",
        "db": "PubMed",
        "db_id": "25478017",
        "db_name": "First-in-man tau vaccine targeting structural determinants essential for pathological tau-tau interaction reduces tau oligomerisation and neurofibrillary degeneration in an Alzheimer's disease model.",
        "first": "Kontsekova E",
        "journal": "Alzheimer's research & therapy",
        "last": "Novak M",
        "pages": "44",
        "volume": "6"
      },
      "evidence": "These results show that the immunisation significantly reduced early forms of pathological tau (represented by monomers, dimers and oligomers) and late forms of pathological tau polymers (represented by paired helical filaments (PHFs)) as well.",
      "key": "716e051b9c7f3bdb770040a39497b56b",
      "line": 156,
      "relation": "decreases",
      "source": 3,
      "target": 2
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHDisease": {
          "Alzheimer Disease": true
        },
        "Species": {
          "10116": true
        }
      },
      "citation": {
        "authors": [
          "Kontsekova E",
          "Kovacech B",
          "Novak M",
          "Novak P",
          "Zilka N"
        ],
        "date": "2014-01-01",
        "db": "PubMed",
        "db_id": "25478017",
        "db_name": "First-in-man tau vaccine targeting structural determinants essential for pathological tau-tau interaction reduces tau oligomerisation and neurofibrillary degeneration in an Alzheimer's disease model.",
        "first": "Kontsekova E",
        "journal": "Alzheimer's research & therapy",
        "last": "Novak M",
        "pages": "44",
        "volume": "6"
      },
      "evidence": "The immunisation significantly improved the total NeuroScale score of the rats treated with tau vaccine compared to the control treatment group (P = 0.047, Figure 4C).",
      "key": "b0ad512ed56391dcbb1230dfe04120ee",
      "line": 192,
      "relation": "negativeCorrelation",
      "source": 3,
      "target": 37
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHDisease": {
          "Alzheimer Disease": true
        },
        "Species": {
          "10116": true
        }
      },
      "citation": {
        "authors": [
          "Kontsekova E",
          "Kovacech B",
          "Novak M",
          "Novak P",
          "Zilka N"
        ],
        "date": "2014-01-01",
        "db": "PubMed",
        "db_id": "25478017",
        "db_name": "First-in-man tau vaccine targeting structural determinants essential for pathological tau-tau interaction reduces tau oligomerisation and neurofibrillary degeneration in an Alzheimer's disease model.",
        "first": "Kontsekova E",
        "journal": "Alzheimer's research & therapy",
        "last": "Novak M",
        "pages": "44",
        "volume": "6"
      },
      "evidence": "To assess possible negative impacts on the immune system, thorough haematological analysis was conducted in acute and chronic toxicology studies in rats and rabbits, respectively. The haematology panel featured the following assessments: erythrocyte count, haemoglobin, haematocrit, mean corpuscular volume, red-cell volume distribution width, mean corpuscular haemoglobin, mean corpuscular haemoglobin concentration, haemoglobin concentration distribution width, reticulocyte count, reticulocyte maturity index, platelet (thrombocyte) count, total leukocyte count, differential leukocyte count (neutrophils, lymphocytes, monocytes, eosinophils, basophils, large unstained cells). Both absolute numbers and relative amounts of white blood cells were assessed. The vaccination did not induce any toxicologically relevant effect on any of the observed parameters.",
      "key": "38c34a065390f7a0b76ce13d8be640fa",
      "line": 212,
      "relation": "causesNoChange",
      "source": 3,
      "target": 38
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHDisease": {
          "Alzheimer Disease": true
        },
        "Species": {
          "10116": true
        }
      },
      "citation": {
        "authors": [
          "Kontsekova E",
          "Kovacech B",
          "Novak M",
          "Novak P",
          "Zilka N"
        ],
        "date": "2014-01-01",
        "db": "PubMed",
        "db_id": "25478017",
        "db_name": "First-in-man tau vaccine targeting structural determinants essential for pathological tau-tau interaction reduces tau oligomerisation and neurofibrillary degeneration in an Alzheimer's disease model.",
        "first": "Kontsekova E",
        "journal": "Alzheimer's research & therapy",
        "last": "Novak M",
        "pages": "44",
        "volume": "6"
      },
      "evidence": "To assess possible negative impacts on the immune system, thorough haematological analysis was conducted in acute and chronic toxicology studies in rats and rabbits, respectively. The haematology panel featured the following assessments: erythrocyte count, haemoglobin, haematocrit, mean corpuscular volume, red-cell volume distribution width, mean corpuscular haemoglobin, mean corpuscular haemoglobin concentration, haemoglobin concentration distribution width, reticulocyte count, reticulocyte maturity index, platelet (thrombocyte) count, total leukocyte count, differential leukocyte count (neutrophils, lymphocytes, monocytes, eosinophils, basophils, large unstained cells). Both absolute numbers and relative amounts of white blood cells were assessed. The vaccination did not induce any toxicologically relevant effect on any of the observed parameters.",
      "key": "18bca73ddcd984e36725d2d910e152c7",
      "line": 213,
      "relation": "causesNoChange",
      "source": 3,
      "target": 7
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHDisease": {
          "Alzheimer Disease": true
        },
        "Species": {
          "10116": true
        }
      },
      "citation": {
        "authors": [
          "Kontsekova E",
          "Kovacech B",
          "Novak M",
          "Novak P",
          "Zilka N"
        ],
        "date": "2014-01-01",
        "db": "PubMed",
        "db_id": "25478017",
        "db_name": "First-in-man tau vaccine targeting structural determinants essential for pathological tau-tau interaction reduces tau oligomerisation and neurofibrillary degeneration in an Alzheimer's disease model.",
        "first": "Kontsekova E",
        "journal": "Alzheimer's research & therapy",
        "last": "Novak M",
        "pages": "44",
        "volume": "6"
      },
      "evidence": "To assess possible negative impacts on the immune system, thorough haematological analysis was conducted in acute and chronic toxicology studies in rats and rabbits, respectively. The haematology panel featured the following assessments: erythrocyte count, haemoglobin, haematocrit, mean corpuscular volume, red-cell volume distribution width, mean corpuscular haemoglobin, mean corpuscular haemoglobin concentration, haemoglobin concentration distribution width, reticulocyte count, reticulocyte maturity index, platelet (thrombocyte) count, total leukocyte count, differential leukocyte count (neutrophils, lymphocytes, monocytes, eosinophils, basophils, large unstained cells). Both absolute numbers and relative amounts of white blood cells were assessed. The vaccination did not induce any toxicologically relevant effect on any of the observed parameters.",
      "key": "81348e72ecbdff6bfa500f46aefc84f8",
      "line": 214,
      "relation": "causesNoChange",
      "source": 3,
      "target": 39
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHDisease": {
          "Alzheimer Disease": true
        },
        "Species": {
          "10116": true
        }
      },
      "citation": {
        "authors": [
          "Kontsekova E",
          "Kovacech B",
          "Novak M",
          "Novak P",
          "Zilka N"
        ],
        "date": "2014-01-01",
        "db": "PubMed",
        "db_id": "25478017",
        "db_name": "First-in-man tau vaccine targeting structural determinants essential for pathological tau-tau interaction reduces tau oligomerisation and neurofibrillary degeneration in an Alzheimer's disease model.",
        "first": "Kontsekova E",
        "journal": "Alzheimer's research & therapy",
        "last": "Novak M",
        "pages": "44",
        "volume": "6"
      },
      "evidence": "To assess possible negative impacts on the immune system, thorough haematological analysis was conducted in acute and chronic toxicology studies in rats and rabbits, respectively. The haematology panel featured the following assessments: erythrocyte count, haemoglobin, haematocrit, mean corpuscular volume, red-cell volume distribution width, mean corpuscular haemoglobin, mean corpuscular haemoglobin concentration, haemoglobin concentration distribution width, reticulocyte count, reticulocyte maturity index, platelet (thrombocyte) count, total leukocyte count, differential leukocyte count (neutrophils, lymphocytes, monocytes, eosinophils, basophils, large unstained cells). Both absolute numbers and relative amounts of white blood cells were assessed. The vaccination did not induce any toxicologically relevant effect on any of the observed parameters.",
      "key": "33785f49bd998156088eba491744643b",
      "line": 215,
      "relation": "causesNoChange",
      "source": 3,
      "target": 42
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHDisease": {
          "Alzheimer Disease": true
        },
        "Species": {
          "10116": true
        }
      },
      "citation": {
        "authors": [
          "Kontsekova E",
          "Kovacech B",
          "Novak M",
          "Novak P",
          "Zilka N"
        ],
        "date": "2014-01-01",
        "db": "PubMed",
        "db_id": "25478017",
        "db_name": "First-in-man tau vaccine targeting structural determinants essential for pathological tau-tau interaction reduces tau oligomerisation and neurofibrillary degeneration in an Alzheimer's disease model.",
        "first": "Kontsekova E",
        "journal": "Alzheimer's research & therapy",
        "last": "Novak M",
        "pages": "44",
        "volume": "6"
      },
      "evidence": "To assess possible negative impacts on the immune system, thorough haematological analysis was conducted in acute and chronic toxicology studies in rats and rabbits, respectively. The haematology panel featured the following assessments: erythrocyte count, haemoglobin, haematocrit, mean corpuscular volume, red-cell volume distribution width, mean corpuscular haemoglobin, mean corpuscular haemoglobin concentration, haemoglobin concentration distribution width, reticulocyte count, reticulocyte maturity index, platelet (thrombocyte) count, total leukocyte count, differential leukocyte count (neutrophils, lymphocytes, monocytes, eosinophils, basophils, large unstained cells). Both absolute numbers and relative amounts of white blood cells were assessed. The vaccination did not induce any toxicologically relevant effect on any of the observed parameters.",
      "key": "6c149cfe82ae2d9e63c2da248d62a28f",
      "line": 216,
      "relation": "causesNoChange",
      "source": 3,
      "target": 41
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHDisease": {
          "Alzheimer Disease": true
        },
        "Species": {
          "10116": true
        }
      },
      "citation": {
        "authors": [
          "Kontsekova E",
          "Kovacech B",
          "Novak M",
          "Novak P",
          "Zilka N"
        ],
        "date": "2014-01-01",
        "db": "PubMed",
        "db_id": "25478017",
        "db_name": "First-in-man tau vaccine targeting structural determinants essential for pathological tau-tau interaction reduces tau oligomerisation and neurofibrillary degeneration in an Alzheimer's disease model.",
        "first": "Kontsekova E",
        "journal": "Alzheimer's research & therapy",
        "last": "Novak M",
        "pages": "44",
        "volume": "6"
      },
      "evidence": "To assess possible negative impacts on the immune system, thorough haematological analysis was conducted in acute and chronic toxicology studies in rats and rabbits, respectively. The haematology panel featured the following assessments: erythrocyte count, haemoglobin, haematocrit, mean corpuscular volume, red-cell volume distribution width, mean corpuscular haemoglobin, mean corpuscular haemoglobin concentration, haemoglobin concentration distribution width, reticulocyte count, reticulocyte maturity index, platelet (thrombocyte) count, total leukocyte count, differential leukocyte count (neutrophils, lymphocytes, monocytes, eosinophils, basophils, large unstained cells). Both absolute numbers and relative amounts of white blood cells were assessed. The vaccination did not induce any toxicologically relevant effect on any of the observed parameters.",
      "key": "ca7223450d426413d81890ab81bf7f5a",
      "line": 217,
      "relation": "causesNoChange",
      "source": 3,
      "target": 40
    },
    {
      "key": "8f9038a6274c1cbd2db4fafa425fb926",
      "relation": "partOf",
      "source": 25,
      "target": 15
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHDisease": {
          "Alzheimer Disease": true
        },
        "Species": {
          "10116": true
        }
      },
      "citation": {
        "authors": [
          "Kontsekova E",
          "Kovacech B",
          "Novak M",
          "Novak P",
          "Zilka N"
        ],
        "date": "2014-01-01",
        "db": "PubMed",
        "db_id": "25478017",
        "db_name": "First-in-man tau vaccine targeting structural determinants essential for pathological tau-tau interaction reduces tau oligomerisation and neurofibrillary degeneration in an Alzheimer's disease model.",
        "first": "Kontsekova E",
        "journal": "Alzheimer's research & therapy",
        "last": "Novak M",
        "pages": "44",
        "volume": "6"
      },
      "evidence": "Vaccination of rats with the tau peptide vaccine preferentially induced formation of IgG1 antibody isotypes specific to mis-disordered tau (151-391/4R) (Figure 1C), indicating a predominant type 2 helper T cell (Th2) type of immune response.",
      "key": "7e0e2b24ec4a9230e1896835168db262",
      "line": 109,
      "relation": "increases",
      "source": 25,
      "target": 36
    },
    {
      "key": "a4eb252fb2b9b5c5a8ef80b706ba810d",
      "relation": "hasVariant",
      "source": 24,
      "target": 25
    },
    {
      "key": "aab959888044d4e0432c8949ade6562a",
      "relation": "partOf",
      "source": 24,
      "target": 14
    },
    {
      "key": "bcbc158e44115138b8067f00d187c117",
      "relation": "partOf",
      "source": 22,
      "target": 13
    },
    {
      "key": "00bf8b873b1e760d4d165f892f95f1d8",
      "relation": "partOf",
      "source": 22,
      "target": 17
    },
    {
      "key": "c11f6b4605ca5874ce59e0fd101e4b37",
      "relation": "partOf",
      "source": 22,
      "target": 18
    },
    {
      "key": "822d404e690eb79f6deaa46c61b4b071",
      "relation": "partOf",
      "source": 22,
      "target": 16
    },
    {
      "key": "03dae3cff5fc9dba8f02debf3e4ab797",
      "relation": "hasVariant",
      "source": 21,
      "target": 22
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHDisease": {
          "Alzheimer Disease": true
        },
        "Species": {
          "10116": true
        }
      },
      "citation": {
        "authors": [
          "Kontsekova E",
          "Kovacech B",
          "Novak M",
          "Novak P",
          "Zilka N"
        ],
        "date": "2014-01-01",
        "db": "PubMed",
        "db_id": "25478017",
        "db_name": "First-in-man tau vaccine targeting structural determinants essential for pathological tau-tau interaction reduces tau oligomerisation and neurofibrillary degeneration in an Alzheimer's disease model.",
        "first": "Kontsekova E",
        "journal": "Alzheimer's research & therapy",
        "last": "Novak M",
        "pages": "44",
        "volume": "6"
      },
      "evidence": "Vaccination with tau vaccine carrying DC8E8 epitope induced antibodies preferentially recognising mis-disordered tau protein, thus discriminating between pathological and physiological tau.",
      "key": "6fa22f30e37489d0d861bd8e8c2298e5",
      "line": 99,
      "relation": "increases",
      "source": 12,
      "target": 8
    },
    {
      "key": "4efdc10db2235939dfe2b7d4d34e9d79",
      "relation": "partOf",
      "source": 4,
      "target": 12
    },
    {
      "key": "f63704e1a12627c17fc05221bedc23ec",
      "relation": "partOf",
      "source": 8,
      "target": 17
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHDisease": {
          "Alzheimer Disease": true
        },
        "Species": {
          "10116": true
        }
      },
      "citation": {
        "authors": [
          "Kontsekova E",
          "Kovacech B",
          "Novak M",
          "Novak P",
          "Zilka N"
        ],
        "date": "2014-01-01",
        "db": "PubMed",
        "db_id": "25478017",
        "db_name": "First-in-man tau vaccine targeting structural determinants essential for pathological tau-tau interaction reduces tau oligomerisation and neurofibrillary degeneration in an Alzheimer's disease model.",
        "first": "Kontsekova E",
        "journal": "Alzheimer's research & therapy",
        "last": "Novak M",
        "pages": "44",
        "volume": "6"
      },
      "evidence": "Vaccination with tau vaccine carrying DC8E8 epitope induced antibodies preferentially recognising mis-disordered tau protein, thus discriminating between pathological and physiological tau.",
      "key": "7fb7716e96b09c6b87782a091ee7cd8d",
      "line": 100,
      "relation": "positiveCorrelation",
      "source": 8,
      "target": 17
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHDisease": {
          "Alzheimer Disease": true
        },
        "Species": {
          "10116": true
        }
      },
      "citation": {
        "authors": [
          "Kontsekova E",
          "Kovacech B",
          "Novak M",
          "Novak P",
          "Zilka N"
        ],
        "date": "2014-01-01",
        "db": "PubMed",
        "db_id": "25478017",
        "db_name": "First-in-man tau vaccine targeting structural determinants essential for pathological tau-tau interaction reduces tau oligomerisation and neurofibrillary degeneration in an Alzheimer's disease model.",
        "first": "Kontsekova E",
        "journal": "Alzheimer's research & therapy",
        "last": "Novak M",
        "pages": "44",
        "volume": "6"
      },
      "evidence": "Vaccination with tau vaccine carrying DC8E8 epitope induced antibodies preferentially recognising mis-disordered tau protein, thus discriminating between pathological and physiological tau.",
      "key": "e675685947a390a6eb8ea0b1c3e1a64b",
      "line": 100,
      "relation": "positiveCorrelation",
      "source": 17,
      "target": 8
    },
    {
      "key": "c86d4a0e500bf85351d407c82e7a6f0f",
      "relation": "partOf",
      "source": 36,
      "target": 18
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHDisease": {
          "Alzheimer Disease": true
        },
        "Species": {
          "10116": true
        }
      },
      "citation": {
        "authors": [
          "Kontsekova E",
          "Kovacech B",
          "Novak M",
          "Novak P",
          "Zilka N"
        ],
        "date": "2014-01-01",
        "db": "PubMed",
        "db_id": "25478017",
        "db_name": "First-in-man tau vaccine targeting structural determinants essential for pathological tau-tau interaction reduces tau oligomerisation and neurofibrillary degeneration in an Alzheimer's disease model.",
        "first": "Kontsekova E",
        "journal": "Alzheimer's research & therapy",
        "last": "Novak M",
        "pages": "44",
        "volume": "6"
      },
      "evidence": "Vaccination of rats with the tau peptide vaccine preferentially induced formation of IgG1 antibody isotypes specific to mis-disordered tau (151-391/4R) (Figure 1C), indicating a predominant type 2 helper T cell (Th2) type of immune response.",
      "key": "1b6b412611f9d94dde980f368763aab7",
      "line": 110,
      "relation": "increases",
      "source": 36,
      "target": 18
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHDisease": {
          "Alzheimer Disease": true
        },
        "Species": {
          "10116": true
        }
      },
      "citation": {
        "authors": [
          "Kontsekova E",
          "Kovacech B",
          "Novak M",
          "Novak P",
          "Zilka N"
        ],
        "date": "2014-01-01",
        "db": "PubMed",
        "db_id": "25478017",
        "db_name": "First-in-man tau vaccine targeting structural determinants essential for pathological tau-tau interaction reduces tau oligomerisation and neurofibrillary degeneration in an Alzheimer's disease model.",
        "first": "Kontsekova E",
        "journal": "Alzheimer's research & therapy",
        "last": "Novak M",
        "pages": "44",
        "volume": "6"
      },
      "evidence": "Vaccination of rats with the tau peptide vaccine preferentially induced formation of IgG1 antibody isotypes specific to mis-disordered tau (151-391/4R) (Figure 1C), indicating a predominant type 2 helper T cell (Th2) type of immune response.",
      "key": "a9941cd690950de669b27fe7561ee089",
      "line": 111,
      "relation": "increases",
      "source": 6,
      "target": 16
    },
    {
      "key": "22271949d19259d63b558818efa279e9",
      "relation": "partOf",
      "source": 5,
      "target": 16
    },
    {
      "key": "292d891b99654df1ccdeeca6c87abebf",
      "relation": "hasVariant",
      "source": 27,
      "target": 28
    },
    {
      "key": "983520e8019a71dbbe095346422716f6",
      "relation": "hasVariant",
      "source": 27,
      "target": 34
    },
    {
      "key": "13995767904f2c704ae2c85b287ed5eb",
      "relation": "hasVariant",
      "source": 27,
      "target": 35
    },
    {
      "key": "0e0ec3a09e8df8d002dd41b58ef30e38",
      "relation": "hasVariant",
      "source": 27,
      "target": 29
    },
    {
      "key": "66af6af91bc9c8705b42c7338defb2de",
      "relation": "hasVariant",
      "source": 27,
      "target": 32
    },
    {
      "key": "c40aee43d27f1806c59dcbf2b7ba2c1a",
      "relation": "hasVariant",
      "source": 27,
      "target": 31
    },
    {
      "key": "6e455396ea0f9f4eca01e280ccbdcfc3",
      "relation": "partOf",
      "source": 27,
      "target": 19
    },
    {
      "key": "6acefc59f17f5c29c97633d639b71e01",
      "relation": "partOf",
      "source": 27,
      "target": 20
    },
    {
      "key": "706ef101cb24bd226ca7ca8bfd47fca9",
      "relation": "hasVariant",
      "source": 27,
      "target": 33
    },
    {
      "key": "a10680e68dbec5aebf32be45eac6c383",
      "relation": "hasVariant",
      "source": 27,
      "target": 30
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHDisease": {
          "Alzheimer Disease": true
        },
        "Species": {
          "10116": true
        }
      },
      "citation": {
        "authors": [
          "Kontsekova E",
          "Kovacech B",
          "Novak M",
          "Novak P",
          "Zilka N"
        ],
        "date": "2014-01-01",
        "db": "PubMed",
        "db_id": "25478017",
        "db_name": "First-in-man tau vaccine targeting structural determinants essential for pathological tau-tau interaction reduces tau oligomerisation and neurofibrillary degeneration in an Alzheimer's disease model.",
        "first": "Kontsekova E",
        "journal": "Alzheimer's research & therapy",
        "last": "Novak M",
        "pages": "44",
        "volume": "6"
      },
      "evidence": "These results show that the immunisation significantly reduced early forms of pathological tau (represented by monomers, dimers and oligomers) and late forms of pathological tau polymers (represented by paired helical filaments (PHFs)) as well.",
      "key": "285a5190a726379d297605c7fd611eac",
      "line": 155,
      "relation": "increases",
      "source": 26,
      "target": 43
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHDisease": {
          "Alzheimer Disease": true
        },
        "Species": {
          "10116": true
        }
      },
      "citation": {
        "authors": [
          "Kontsekova E",
          "Kovacech B",
          "Novak M",
          "Novak P",
          "Zilka N"
        ],
        "date": "2014-01-01",
        "db": "PubMed",
        "db_id": "25478017",
        "db_name": "First-in-man tau vaccine targeting structural determinants essential for pathological tau-tau interaction reduces tau oligomerisation and neurofibrillary degeneration in an Alzheimer's disease model.",
        "first": "Kontsekova E",
        "journal": "Alzheimer's research & therapy",
        "last": "Novak M",
        "pages": "44",
        "volume": "6"
      },
      "evidence": "These results show that the immunisation significantly reduced early forms of pathological tau (represented by monomers, dimers and oligomers) and late forms of pathological tau polymers (represented by paired helical filaments (PHFs)) as well.",
      "key": "5fd5fb03d6628c4c214c01ed60b1b47d",
      "line": 153,
      "relation": "increases",
      "source": 19,
      "target": 43
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHDisease": {
          "Alzheimer Disease": true
        },
        "Species": {
          "10116": true
        }
      },
      "citation": {
        "authors": [
          "Kontsekova E",
          "Kovacech B",
          "Novak M",
          "Novak P",
          "Zilka N"
        ],
        "date": "2014-01-01",
        "db": "PubMed",
        "db_id": "25478017",
        "db_name": "First-in-man tau vaccine targeting structural determinants essential for pathological tau-tau interaction reduces tau oligomerisation and neurofibrillary degeneration in an Alzheimer's disease model.",
        "first": "Kontsekova E",
        "journal": "Alzheimer's research & therapy",
        "last": "Novak M",
        "pages": "44",
        "volume": "6"
      },
      "evidence": "These results show that the immunisation significantly reduced early forms of pathological tau (represented by monomers, dimers and oligomers) and late forms of pathological tau polymers (represented by paired helical filaments (PHFs)) as well.",
      "key": "a6045d3728128ff43c52cc56e2d5ae6a",
      "line": 154,
      "relation": "increases",
      "source": 20,
      "target": 43
    },
    {
      "key": "a4ddd7cbc37dd088379ebc1b72de9b55",
      "relation": "partOf",
      "source": 0,
      "target": 9
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHAnatomy": {
          "Brain": true
        },
        "MeSHDisease": {
          "Alzheimer Disease": true
        },
        "Species": {
          "10116": true
        }
      },
      "citation": {
        "authors": [
          "Kontsekova E",
          "Kovacech B",
          "Novak M",
          "Novak P",
          "Zilka N"
        ],
        "date": "2014-01-01",
        "db": "PubMed",
        "db_id": "25478017",
        "db_name": "First-in-man tau vaccine targeting structural determinants essential for pathological tau-tau interaction reduces tau oligomerisation and neurofibrillary degeneration in an Alzheimer's disease model.",
        "first": "Kontsekova E",
        "journal": "Alzheimer's research & therapy",
        "last": "Novak M",
        "pages": "44",
        "volume": "6"
      },
      "evidence": "We found that several monoclonal antibodies, including TAU5 (part A in Additional file 2), HT7 (B in Additional file 2), pT212 (C in Additional file 2) and pS214 (D in Additional file 2), recognised neurofibrillary degeneration in transgenic rat brain.",
      "key": "3e9fd4c908760824d0f9e696ec0f2781",
      "line": 169,
      "relation": "increases",
      "source": 0,
      "target": 9
    },
    {
      "key": "2779b8a7b82058063a7e9d8e3ff0c086",
      "relation": "partOf",
      "source": 1,
      "target": 9
    },
    {
      "key": "63796ff6ca47a7e96ea457bd771a9eef",
      "relation": "partOf",
      "source": 1,
      "target": 11
    },
    {
      "key": "10c0a4687f0e9344271ddf6995e478ff",
      "relation": "partOf",
      "source": 1,
      "target": 10
    },
    {
      "key": "2f0a52f8a9a98825c99d89ec8b394b0e",
      "relation": "partOf",
      "source": 33,
      "target": 11
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHAnatomy": {
          "Brain": true
        },
        "MeSHDisease": {
          "Alzheimer Disease": true
        },
        "Species": {
          "10116": true
        }
      },
      "citation": {
        "authors": [
          "Kontsekova E",
          "Kovacech B",
          "Novak M",
          "Novak P",
          "Zilka N"
        ],
        "date": "2014-01-01",
        "db": "PubMed",
        "db_id": "25478017",
        "db_name": "First-in-man tau vaccine targeting structural determinants essential for pathological tau-tau interaction reduces tau oligomerisation and neurofibrillary degeneration in an Alzheimer's disease model.",
        "first": "Kontsekova E",
        "journal": "Alzheimer's research & therapy",
        "last": "Novak M",
        "pages": "44",
        "volume": "6"
      },
      "evidence": "We found that several monoclonal antibodies, including TAU5 (part A in Additional file 2), HT7 (B in Additional file 2), pT212 (C in Additional file 2) and pS214 (D in Additional file 2), recognised neurofibrillary degeneration in transgenic rat brain.",
      "key": "ea2b567f844112c14bdb9bb688771507",
      "line": 170,
      "relation": "increases",
      "source": 33,
      "target": 11
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHDisease": {
          "Alzheimer Disease": true
        },
        "Species": {
          "10116": true
        }
      },
      "citation": {
        "authors": [
          "Kontsekova E",
          "Kovacech B",
          "Novak M",
          "Novak P",
          "Zilka N"
        ],
        "date": "2014-01-01",
        "db": "PubMed",
        "db_id": "25478017",
        "db_name": "First-in-man tau vaccine targeting structural determinants essential for pathological tau-tau interaction reduces tau oligomerisation and neurofibrillary degeneration in an Alzheimer's disease model.",
        "first": "Kontsekova E",
        "journal": "Alzheimer's research & therapy",
        "last": "Novak M",
        "pages": "44",
        "volume": "6"
      },
      "evidence": "Immunostaining with AT8, pT212 and pS214 showed that immunisation reduced the number of transgenic rats with extensive neurofibrillary degeneration by 55% (AT8, pT212; Figure 3C and F) or by 77% (pS214; Figure 3I).",
      "key": "615a9eb780a4f53f573c5901dbf6ee0e",
      "line": 182,
      "relation": "decreases",
      "source": 33,
      "target": 1
    },
    {
      "key": "68f19e1a955d3b04fcb3ad3ae7d7ff52",
      "relation": "partOf",
      "source": 30,
      "target": 10
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHAnatomy": {
          "Brain": true
        },
        "MeSHDisease": {
          "Alzheimer Disease": true
        },
        "Species": {
          "10116": true
        }
      },
      "citation": {
        "authors": [
          "Kontsekova E",
          "Kovacech B",
          "Novak M",
          "Novak P",
          "Zilka N"
        ],
        "date": "2014-01-01",
        "db": "PubMed",
        "db_id": "25478017",
        "db_name": "First-in-man tau vaccine targeting structural determinants essential for pathological tau-tau interaction reduces tau oligomerisation and neurofibrillary degeneration in an Alzheimer's disease model.",
        "first": "Kontsekova E",
        "journal": "Alzheimer's research & therapy",
        "last": "Novak M",
        "pages": "44",
        "volume": "6"
      },
      "evidence": "We found that several monoclonal antibodies, including TAU5 (part A in Additional file 2), HT7 (B in Additional file 2), pT212 (C in Additional file 2) and pS214 (D in Additional file 2), recognised neurofibrillary degeneration in transgenic rat brain.",
      "key": "29d41d8efb599b6cf1508cde4fa04d69",
      "line": 171,
      "relation": "increases",
      "source": 30,
      "target": 10
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHDisease": {
          "Alzheimer Disease": true
        },
        "Species": {
          "10116": true
        }
      },
      "citation": {
        "authors": [
          "Kontsekova E",
          "Kovacech B",
          "Novak M",
          "Novak P",
          "Zilka N"
        ],
        "date": "2014-01-01",
        "db": "PubMed",
        "db_id": "25478017",
        "db_name": "First-in-man tau vaccine targeting structural determinants essential for pathological tau-tau interaction reduces tau oligomerisation and neurofibrillary degeneration in an Alzheimer's disease model.",
        "first": "Kontsekova E",
        "journal": "Alzheimer's research & therapy",
        "last": "Novak M",
        "pages": "44",
        "volume": "6"
      },
      "evidence": "Immunostaining with AT8, pT212 and pS214 showed that immunisation reduced the number of transgenic rats with extensive neurofibrillary degeneration by 55% (AT8, pT212; Figure 3C and F) or by 77% (pS214; Figure 3I).",
      "key": "9bbbe39a70266fdf50e9fdbda7c25f72",
      "line": 183,
      "relation": "decreases",
      "source": 30,
      "target": 1
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHDisease": {
          "Alzheimer Disease": true
        },
        "Species": {
          "10116": true
        }
      },
      "citation": {
        "authors": [
          "Kontsekova E",
          "Kovacech B",
          "Novak M",
          "Novak P",
          "Zilka N"
        ],
        "date": "2014-01-01",
        "db": "PubMed",
        "db_id": "25478017",
        "db_name": "First-in-man tau vaccine targeting structural determinants essential for pathological tau-tau interaction reduces tau oligomerisation and neurofibrillary degeneration in an Alzheimer's disease model.",
        "first": "Kontsekova E",
        "journal": "Alzheimer's research & therapy",
        "last": "Novak M",
        "pages": "44",
        "volume": "6"
      },
      "evidence": "Immunostaining with AT8, pT212 and pS214 showed that immunisation reduced the number of transgenic rats with extensive neurofibrillary degeneration by 55% (AT8, pT212; Figure 3C and F) or by 77% (pS214; Figure 3I).",
      "key": "8940a2481e3b9610944c118de215c0a1",
      "line": 181,
      "relation": "decreases",
      "source": 23,
      "target": 1
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHDisease": {
          "Alzheimer Disease": true
        },
        "Species": {
          "10116": true
        }
      },
      "citation": {
        "authors": [
          "Kontsekova E",
          "Kovacech B",
          "Novak M",
          "Novak P",
          "Zilka N"
        ],
        "date": "2014-01-01",
        "db": "PubMed",
        "db_id": "25478017",
        "db_name": "First-in-man tau vaccine targeting structural determinants essential for pathological tau-tau interaction reduces tau oligomerisation and neurofibrillary degeneration in an Alzheimer's disease model.",
        "first": "Kontsekova E",
        "journal": "Alzheimer's research & therapy",
        "last": "Novak M",
        "pages": "44",
        "volume": "6"
      },
      "evidence": "The immunisation significantly improved the total NeuroScale score of the rats treated with tau vaccine compared to the control treatment group (P = 0.047, Figure 4C).",
      "key": "f2c22360fb03b2f52af3c6485ca11968",
      "line": 192,
      "relation": "negativeCorrelation",
      "source": 37,
      "target": 3
    }
  ],
  "multigraph": true,
  "nodes": [
    {
      "bel": "a(CONSO:\"Tau antibody, HT7\")",
      "concept": {
        "name": "Tau antibody, HT7",
        "namespace": "CONSO"
      },
      "function": "Abundance",
      "id": "ead85696fe03925d2f2fa5b3e944803e"
    },
    {
      "bel": "a(CONSO:\"Tau fibrils\")",
      "concept": {
        "name": "Tau fibrils",
        "namespace": "CONSO"
      },
      "function": "Abundance",
      "id": "1b18e2b527ac0db7353b67d4534c033e"
    },
    {
      "bel": "a(CONSO:\"paired helical filaments\")",
      "concept": {
        "name": "paired helical filaments",
        "namespace": "CONSO"
      },
      "function": "Abundance",
      "id": "cf5d166157778ce378f93f26ae7c2f3c"
    },
    {
      "bel": "a(CONSO:AADvac1)",
      "concept": {
        "name": "AADvac1",
        "namespace": "CONSO"
      },
      "function": "Abundance",
      "id": "02805d0abde238880ce43b1ddb680cd0"
    },
    {
      "bel": "a(CONSO:DC8E8)",
      "concept": {
        "name": "DC8E8",
        "namespace": "CONSO"
      },
      "function": "Abundance",
      "id": "6fda92ea9e60923c401c3b2b0526052a"
    },
    {
      "bel": "a(MESH:\"Immunoglobulin G\")",
      "concept": {
        "name": "Immunoglobulin G",
        "namespace": "MESH"
      },
      "function": "Abundance",
      "id": "ed6b199fc0a3b814d8ce805fa9964dca"
    },
    {
      "bel": "bp(GO:\"T-helper 2 cell activation\")",
      "concept": {
        "name": "T-helper 2 cell activation",
        "namespace": "GO"
      },
      "function": "BiologicalProcess",
      "id": "5013d0e706f82c2ccae09b5bca3c6a0d"
    },
    {
      "bel": "complex(GO:\"hemoglobin complex\")",
      "concept": {
        "name": "hemoglobin complex",
        "namespace": "GO"
      },
      "function": "Complex",
      "id": "1d7bf76abb8eb1cce773d9908e9addac"
    },
    {
      "bel": "complex(GO:\"immunoglobulin complex\")",
      "concept": {
        "name": "immunoglobulin complex",
        "namespace": "GO"
      },
      "function": "Complex",
      "id": "5413821c04f8d591fce4a58eea7a4fc6"
    },
    {
      "bel": "complex(a(CONSO:\"Tau antibody, HT7\"), a(CONSO:\"Tau fibrils\"))",
      "function": "Complex",
      "id": "162c3ea81fcccf350aa8c8cf51178c75",
      "members": [
        {
          "bel": "a(CONSO:\"Tau antibody, HT7\")",
          "concept": {
            "name": "Tau antibody, HT7",
            "namespace": "CONSO"
          },
          "function": "Abundance",
          "id": "ead85696fe03925d2f2fa5b3e944803e"
        },
        {
          "bel": "a(CONSO:\"Tau fibrils\")",
          "concept": {
            "name": "Tau fibrils",
            "namespace": "CONSO"
          },
          "function": "Abundance",
          "id": "1b18e2b527ac0db7353b67d4534c033e"
        }
      ]
    },
    {
      "bel": "complex(a(CONSO:\"Tau fibrils\"), p(HGNC:MAPT, pmod(Ph, Ser, 214)))",
      "function": "Complex",
      "id": "663fd473dc68627195efa1ae85f7707f",
      "members": [
        {
          "bel": "a(CONSO:\"Tau fibrils\")",
          "concept": {
            "name": "Tau fibrils",
            "namespace": "CONSO"
          },
          "function": "Abundance",
          "id": "1b18e2b527ac0db7353b67d4534c033e"
        },
        {
          "bel": "p(HGNC:MAPT, pmod(Ph, Ser, 214))",
          "concept": {
            "name": "MAPT",
            "namespace": "HGNC"
          },
          "function": "Protein",
          "id": "db0314eacd12a1283c87a6e94b8058a7",
          "variants": [
            {
              "code": "Ser",
              "concept": {
                "name": "Ph",
                "namespace": "bel"
              },
              "kind": "pmod",
              "pos": 214
            }
          ]
        }
      ]
    },
    {
      "bel": "complex(a(CONSO:\"Tau fibrils\"), p(HGNC:MAPT, pmod(Ph, Thr, 212)))",
      "function": "Complex",
      "id": "9d168ed84cfe5f1a421b3c3716a6d4c7",
      "members": [
        {
          "bel": "a(CONSO:\"Tau fibrils\")",
          "concept": {
            "name": "Tau fibrils",
            "namespace": "CONSO"
          },
          "function": "Abundance",
          "id": "1b18e2b527ac0db7353b67d4534c033e"
        },
        {
          "bel": "p(HGNC:MAPT, pmod(Ph, Thr, 212))",
          "concept": {
            "name": "MAPT",
            "namespace": "HGNC"
          },
          "function": "Protein",
          "id": "e0c94e8066a56a138256460ca89ac300",
          "variants": [
            {
              "code": "Thr",
              "concept": {
                "name": "Ph",
                "namespace": "bel"
              },
              "kind": "pmod",
              "pos": 212
            }
          ]
        }
      ]
    },
    {
      "bel": "complex(a(CONSO:AADvac1), a(CONSO:DC8E8))",
      "function": "Complex",
      "id": "fb67629845d666bdef8b065edcce6b42",
      "members": [
        {
          "bel": "a(CONSO:AADvac1)",
          "concept": {
            "name": "AADvac1",
            "namespace": "CONSO"
          },
          "function": "Abundance",
          "id": "02805d0abde238880ce43b1ddb680cd0"
        },
        {
          "bel": "a(CONSO:DC8E8)",
          "concept": {
            "name": "DC8E8",
            "namespace": "CONSO"
          },
          "function": "Abundance",
          "id": "6fda92ea9e60923c401c3b2b0526052a"
        }
      ]
    },
    {
      "bel": "complex(a(CONSO:AADvac1), p(CONSO:\"4R tau\", var(\"p.151_391del\")))",
      "function": "Complex",
      "id": "f90a980f7e9ce9ff471d6e67603ad09f",
      "members": [
        {
          "bel": "a(CONSO:AADvac1)",
          "concept": {
            "name": "AADvac1",
            "namespace": "CONSO"
          },
          "function": "Abundance",
          "id": "02805d0abde238880ce43b1ddb680cd0"
        },
        {
          "bel": "p(CONSO:\"4R tau\", var(\"p.151_391del\"))",
          "concept": {
            "name": "4R tau",
            "namespace": "CONSO"
          },
          "function": "Protein",
          "id": "4320c8385b07b6a5587b1db2dbc95f6f",
          "variants": [
            {
              "hgvs": "p.151_391del",
              "kind": "hgvs"
            }
          ]
        }
      ]
    },
    {
      "bel": "complex(a(CONSO:AADvac1), p(CONSO:\"Tau isoform F (441 aa)\"))",
      "function": "Complex",
      "id": "2d38483313f9d366b2f8fd9e7964226d",
      "members": [
        {
          "bel": "a(CONSO:AADvac1)",
          "concept": {
            "name": "AADvac1",
            "namespace": "CONSO"
          },
          "function": "Abundance",
          "id": "02805d0abde238880ce43b1ddb680cd0"
        },
        {
          "bel": "p(CONSO:\"Tau isoform F (441 aa)\")",
          "concept": {
            "name": "Tau isoform F (441 aa)",
            "namespace": "CONSO"
          },
          "function": "Protein",
          "id": "83682de7856cc379117e146862b26202"
        }
      ]
    },
    {
      "bel": "complex(a(CONSO:AADvac1), p(CONSO:\"Tau isoform F (441 aa)\", frag(\"?\")))",
      "function": "Complex",
      "id": "66d9b1a71a693e0b98e2e0bd21c12d8d",
      "members": [
        {
          "bel": "a(CONSO:AADvac1)",
          "concept": {
            "name": "AADvac1",
            "namespace": "CONSO"
          },
          "function": "Abundance",
          "id": "02805d0abde238880ce43b1ddb680cd0"
        },
        {
          "bel": "p(CONSO:\"Tau isoform F (441 aa)\", frag(\"?\"))",
          "concept": {
            "name": "Tau isoform F (441 aa)",
            "namespace": "CONSO"
          },
          "function": "Protein",
          "id": "8da97ce08d9e376e6c82af242f74dce7",
          "variants": [
            {
              "kind": "frag",
              "missing": "?"
            }
          ]
        }
      ]
    },
    {
      "bel": "complex(a(MESH:\"Immunoglobulin G\"), p(CONSO:\"4R tau\", var(\"p.151_391del\")))",
      "function": "Complex",
      "id": "2e62e35f8408fd631779623ae3617f8e",
      "members": [
        {
          "bel": "a(MESH:\"Immunoglobulin G\")",
          "concept": {
            "name": "Immunoglobulin G",
            "namespace": "MESH"
          },
          "function": "Abundance",
          "id": "ed6b199fc0a3b814d8ce805fa9964dca"
        },
        {
          "bel": "p(CONSO:\"4R tau\", var(\"p.151_391del\"))",
          "concept": {
            "name": "4R tau",
            "namespace": "CONSO"
          },
          "function": "Protein",
          "id": "4320c8385b07b6a5587b1db2dbc95f6f",
          "variants": [
            {
              "hgvs": "p.151_391del",
              "kind": "hgvs"
            }
          ]
        }
      ]
    },
    {
      "bel": "complex(complex(GO:\"immunoglobulin complex\"), p(CONSO:\"4R tau\", var(\"p.151_391del\")))",
      "function": "Complex",
      "id": "cccdc6a3bff21840d84bc8ad56359fef",
      "members": [
        {
          "bel": "complex(GO:\"immunoglobulin complex\")",
          "concept": {
            "name": "immunoglobulin complex",
            "namespace": "GO"
          },
          "function": "Complex",
          "id": "5413821c04f8d591fce4a58eea7a4fc6"
        },
        {
          "bel": "p(CONSO:\"4R tau\", var(\"p.151_391del\"))",
          "concept": {
            "name": "4R tau",
            "namespace": "CONSO"
          },
          "function": "Protein",
          "id": "4320c8385b07b6a5587b1db2dbc95f6f",
          "variants": [
            {
              "hgvs": "p.151_391del",
              "kind": "hgvs"
            }
          ]
        }
      ]
    },
    {
      "bel": "complex(p(CONSO:\"4R tau\", var(\"p.151_391del\")), p(MESH:\"Immunoglobulin G\"))",
      "function": "Complex",
      "id": "1ff0571b31c8d39cfd7f449d8da76e4a",
      "members": [
        {
          "bel": "p(CONSO:\"4R tau\", var(\"p.151_391del\"))",
          "concept": {
            "name": "4R tau",
            "namespace": "CONSO"
          },
          "function": "Protein",
          "id": "4320c8385b07b6a5587b1db2dbc95f6f",
          "variants": [
            {
              "hgvs": "p.151_391del",
              "kind": "hgvs"
            }
          ]
        },
        {
          "bel": "p(MESH:\"Immunoglobulin G\")",
          "concept": {
            "name": "Immunoglobulin G",
            "namespace": "MESH"
          },
          "function": "Protein",
          "id": "0552597810550378b083a4247508e495"
        }
      ]
    },
    {
      "bel": "complex(p(HGNC:MAPT), p(HGNC:MAPT))",
      "function": "Complex",
      "id": "2218a553afef0da4b62d5115971b2947",
      "members": [
        {
          "bel": "p(HGNC:MAPT)",
          "concept": {
            "name": "MAPT",
            "namespace": "HGNC"
          },
          "function": "Protein",
          "id": "7d1009217050e75d549c8c5aa83309a8"
        },
        {
          "bel": "p(HGNC:MAPT)",
          "concept": {
            "name": "MAPT",
            "namespace": "HGNC"
          },
          "function": "Protein",
          "id": "7d1009217050e75d549c8c5aa83309a8"
        }
      ]
    },
    {
      "bel": "complex(p(HGNC:MAPT), p(HGNC:MAPT), p(HGNC:MAPT))",
      "function": "Complex",
      "id": "efa089e09b3e4ce347cc9721157e9739",
      "members": [
        {
          "bel": "p(HGNC:MAPT)",
          "concept": {
            "name": "MAPT",
            "namespace": "HGNC"
          },
          "function": "Protein",
          "id": "7d1009217050e75d549c8c5aa83309a8"
        },
        {
          "bel": "p(HGNC:MAPT)",
          "concept": {
            "name": "MAPT",
            "namespace": "HGNC"
          },
          "function": "Protein",
          "id": "7d1009217050e75d549c8c5aa83309a8"
        },
        {
          "bel": "p(HGNC:MAPT)",
          "concept": {
            "name": "MAPT",
            "namespace": "HGNC"
          },
          "function": "Protein",
          "id": "7d1009217050e75d549c8c5aa83309a8"
        }
      ]
    },
    {
      "bel": "p(CONSO:\"4R tau\")",
      "concept": {
        "name": "4R tau",
        "namespace": "CONSO"
      },
      "function": "Protein",
      "id": "c5fd156b7c1a309ed11b8dca3e247657"
    },
    {
      "bel": "p(CONSO:\"4R tau\", var(\"p.151_391del\"))",
      "concept": {
        "name": "4R tau",
        "namespace": "CONSO"
      },
      "function": "Protein",
      "id": "4320c8385b07b6a5587b1db2dbc95f6f",
      "variants": [
        {
          "hgvs": "p.151_391del",
          "kind": "hgvs"
        }
      ]
    },
    {
      "bel": "p(CONSO:\"Tau epitope, AT8\")",
      "concept": {
        "name": "Tau epitope, AT8",
        "namespace": "CONSO"
      },
      "function": "Protein",
      "id": "6dd17eb2a65858826878cae123da6085"
    },
    {
      "bel": "p(CONSO:\"Tau isoform F (441 aa)\")",
      "concept": {
        "name": "Tau isoform F (441 aa)",
        "namespace": "CONSO"
      },
      "function": "Protein",
      "id": "83682de7856cc379117e146862b26202"
    },
    {
      "bel": "p(CONSO:\"Tau isoform F (441 aa)\", frag(\"?\"))",
      "concept": {
        "name": "Tau isoform F (441 aa)",
        "namespace": "CONSO"
      },
      "function": "Protein",
      "id": "8da97ce08d9e376e6c82af242f74dce7",
      "variants": [
        {
          "kind": "frag",
          "missing": "?"
        }
      ]
    },
    {
      "bel": "p(CONSO:\"Tau oligomers\")",
      "concept": {
        "name": "Tau oligomers",
        "namespace": "CONSO"
      },
      "function": "Protein",
      "id": "541ac886014140ca02c1076bebd9f2f9"
    },
    {
      "bel": "p(HGNC:MAPT)",
      "concept": {
        "name": "MAPT",
        "namespace": "HGNC"
      },
      "function": "Protein",
      "id": "7d1009217050e75d549c8c5aa83309a8"
    },
    {
      "bel": "p(HGNC:MAPT, frag(\"?\"), pmod(CONSO:hyperphosphorylation))",
      "concept": {
        "name": "MAPT",
        "namespace": "HGNC"
      },
      "function": "Protein",
      "id": "329781b954d5c1e16a026229dd21dbda",
      "variants": [
        {
          "kind": "frag",
          "missing": "?"
        },
        {
          "concept": {
            "name": "hyperphosphorylation",
            "namespace": "CONSO"
          },
          "kind": "pmod"
        }
      ]
    },
    {
      "bel": "p(HGNC:MAPT, pmod(Ph, Ser, 202))",
      "concept": {
        "name": "MAPT",
        "namespace": "HGNC"
      },
      "function": "Protein",
      "id": "cdcc3b3f116c5db02d04ca383584aef0",
      "variants": [
        {
          "code": "Ser",
          "concept": {
            "name": "Ph",
            "namespace": "bel"
          },
          "kind": "pmod",
          "pos": 202
        }
      ]
    },
    {
      "bel": "p(HGNC:MAPT, pmod(Ph, Ser, 214))",
      "concept": {
        "name": "MAPT",
        "namespace": "HGNC"
      },
      "function": "Protein",
      "id": "db0314eacd12a1283c87a6e94b8058a7",
      "variants": [
        {
          "code": "Ser",
          "concept": {
            "name": "Ph",
            "namespace": "bel"
          },
          "kind": "pmod",
          "pos": 214
        }
      ]
    },
    {
      "bel": "p(HGNC:MAPT, pmod(Ph, Thr, 181))",
      "concept": {
        "name": "MAPT",
        "namespace": "HGNC"
      },
      "function": "Protein",
      "id": "0b33aa1bee79f21990b8e145bc2b2088",
      "variants": [
        {
          "code": "Thr",
          "concept": {
            "name": "Ph",
            "namespace": "bel"
          },
          "kind": "pmod",
          "pos": 181
        }
      ]
    },
    {
      "bel": "p(HGNC:MAPT, pmod(Ph, Thr, 205))",
      "concept": {
        "name": "MAPT",
        "namespace": "HGNC"
      },
      "function": "Protein",
      "id": "18a670a34dac41b169d64c4316bdf50c",
      "variants": [
        {
          "code": "Thr",
          "concept": {
            "name": "Ph",
            "namespace": "bel"
          },
          "kind": "pmod",
          "pos": 205
        }
      ]
    },
    {
      "bel": "p(HGNC:MAPT, pmod(Ph, Thr, 212))",
      "concept": {
        "name": "MAPT",
        "namespace": "HGNC"
      },
      "function": "Protein",
      "id": "e0c94e8066a56a138256460ca89ac300",
      "variants": [
        {
          "code": "Thr",
          "concept": {
            "name": "Ph",
            "namespace": "bel"
          },
          "kind": "pmod",
          "pos": 212
        }
      ]
    },
    {
      "bel": "p(HGNC:MAPT, pmod(Ph, Thr, 217))",
      "concept": {
        "name": "MAPT",
        "namespace": "HGNC"
      },
      "function": "Protein",
      "id": "58088efd52bc8a9e1670092d65c9737d",
      "variants": [
        {
          "code": "Thr",
          "concept": {
            "name": "Ph",
            "namespace": "bel"
          },
          "kind": "pmod",
          "pos": 217
        }
      ]
    },
    {
      "bel": "p(HGNC:MAPT, pmod(Ph, Thr, 231))",
      "concept": {
        "name": "MAPT",
        "namespace": "HGNC"
      },
      "function": "Protein",
      "id": "1b27e2cacb75475db2ede3bb5867066c",
      "variants": [
        {
          "code": "Thr",
          "concept": {
            "name": "Ph",
            "namespace": "bel"
          },
          "kind": "pmod",
          "pos": 231
        }
      ]
    },
    {
      "bel": "p(MESH:\"Immunoglobulin G\")",
      "concept": {
        "name": "Immunoglobulin G",
        "namespace": "MESH"
      },
      "function": "Protein",
      "id": "0552597810550378b083a4247508e495"
    },
    {
      "bel": "path(HP:\"Sensorimotor neuropathy\")",
      "concept": {
        "name": "Sensorimotor neuropathy",
        "namespace": "HP"
      },
      "function": "Pathology",
      "id": "5c6d5e81cca806c254e5cc2153cfe391"
    },
    {
      "bel": "path(MESH:\"Erythrocyte Count\")",
      "concept": {
        "name": "Erythrocyte Count",
        "namespace": "MESH"
      },
      "function": "Pathology",
      "id": "abd838c43ca83a1cf0fe73ba4adb9a19"
    },
    {
      "bel": "path(MESH:\"Erythrocyte Indices\")",
      "concept": {
        "name": "Erythrocyte Indices",
        "namespace": "MESH"
      },
      "function": "Pathology",
      "id": "b07e7c65c36332dc9a7c07bacc5784db"
    },
    {
      "bel": "path(MESH:\"Leukocyte Count\")",
      "concept": {
        "name": "Leukocyte Count",
        "namespace": "MESH"
      },
      "function": "Pathology",
      "id": "937e51e6772bf9839ecf880f0147292e"
    },
    {
      "bel": "path(MESH:\"Platelet Count\")",
      "concept": {
        "name": "Platelet Count",
        "namespace": "MESH"
      },
      "function": "Pathology",
      "id": "93d0ba4d1a2d577e14baa829e1f2dd2a"
    },
    {
      "bel": "path(MESH:\"Reticulocyte Count\")",
      "concept": {
        "name": "Reticulocyte Count",
        "namespace": "MESH"
      },
      "function": "Pathology",
      "id": "6bc874ac29bf02a71a0fcb98aa418d93"
    },
    {
      "bel": "path(MESH:Tauopathies)",
      "concept": {
        "name": "Tauopathies",
        "namespace": "MESH"
      },
      "function": "Pathology",
      "id": "e7af59eca49dd3e30ab0fb75db41527a"
    }
  ]
}